Introduction
============

Colorectal cancer (CRC) is the third most common cancer type and is a leading cause of cancer-associated mortality worldwide ([@b1-ol-0-0-11365],[@b2-ol-0-0-11365]). A certain subset of CRC arises from the sequential accumulation of genetic and epigenetic alterations. microRNAs (miRNA/miR) have been revealed as candidates in tumor progression in various cancer types, and changes in their expression levels are consequently being investigated with the purpose of identifying clinical biomarkers ([@b3-ol-0-0-11365]--[@b9-ol-0-0-11365]). miRNAs constitute a class of small, non-coding RNA molecules, 18--27 nucleotides in length that function as post-transcriptional regulators of gene expression, either serving as oncogenes or tumor suppressor genes ([@b10-ol-0-0-11365],[@b11-ol-0-0-11365]). In CRC, several miRNAs are aberrantly expressed and target genes downstream of epidermal growth factor receptor (EGFR) signaling; for example, *miR-143* and *−145* target KRAS and BRAF proteins, respectively ([@b12-ol-0-0-11365]). Nosho *et al* ([@b13-ol-0-0-11365]) revealed that high *miR-31-5p (miR-31)* expression \[*miR-31* has the two subtypes; *miR-31* (*hsa-mir-31-5p*) and *miR-31\** (*hsa-mir-31-3p*)\] was significantly associated with *BRAF* V600E mutation (P\<0.0001) and a poorer prognosis in a large statistical population of 721 patients with CRC. Additionally, downregulation of BRAF protein expression, following transfection of an *miR-31* inhibitor into CRC cells was demonstrated ([@b13-ol-0-0-11365]). Thus, the aforementioned evidence indicates that *miR-31* may regulate the activation of BRAF protein in CRC, and may also serve an important role in the downstream EGFR signaling pathway.

The present study investigated *miR-31* that is significantly associated with advanced CRC with *BRAF* V600E mutation, as the presence of *BRAF* mutations is known to be a poor prognostic factor in CRC ([@b14-ol-0-0-11365]--[@b18-ol-0-0-11365]). According to the results of the microarray analysis, it was revealed that *miR-31* expression is upregulated in *BRAF*-mutant tumors. Therefore, the association between *miR-31* expression levels and *BRAF*-mutant CRCs was further investigated using a dataset retrieved from The Cancer Genome Atlas (TCGA) database. Finally, *miR-31* expression patterns observed in CRC were further supported by investigating the *miR-31* expression level in patients with stage IV CRC.

Materials and methods
=====================

### Patients

From a cohort of 598 patients with CRC, 129 patients with stage IV CRC underwent primary tumor resection before other treatments, such as chemotherapy, radiotherapy or chemoradiotherapy, at Okayama University Hospital (Okayama, Japan) between March 2003 and May 2013. Of these, only 67 patients were evaluated and analyzed in the present study due to availability of both tumors and the paired normal mucosa ([Fig. 1](#f1-ol-0-0-11365){ref-type="fig"}). The tumors and the corresponding normal mucosa were stored at −80°C following preservation with RNA*later*^®^ (Sigma-Aldrich; Merck KGaA). Clinical, pathological and survival data were extracted from medical records. The pathological stage was determined according to the International Union Against Cancer TNM staging system (seventh edition) ([@b19-ol-0-0-11365]). Institutional review board approval was granted by the Ethics Committee of Okayama University, and written informed consent was provided from all patients for the use of their tissues and clinical data.

### DNA and RNA extraction

DNA was extracted from 67 fresh-frozen paired tumor and healthy colonic mucosal tissue specimens, which were obtained from a site adjacent to the primary tumor, \>10 cm from the tumor border. DNA from the fresh-frozen tissue specimens was extracted using a QIAamp DNA Mini kit (Qiagen, Inc.) according to the manufacturer\'s protocol. Total miRNA was isolated from frozen tissue specimens preserved by RNAlater^®^ (Sigma-Aldrich; Merck KGaA) using a miRNeasy Mini kit (Qiagen, Inc.) and quality and quantity were confirmed using a Qubit fluorometer (Qubit 2.0 or 3.0; Invitrogen; Thermo Fisher Scientific, Inc.).

### BRAF and KRAS mutation analyses

A *BRAF* mutation in codon 600 and *KRAS* mutations in codons 12 and 13 were analyzed by direct sequencing using purified DNA from fresh-frozen tissues of each patient. The specific primer sequences and PCR conditions have been described previously ([@b20-ol-0-0-11365]). The PCR products were purified using a QIAquick PCR purification kit (Qiagen, Inc.) according to the manufacturer\'s protocol and were directly sequenced on an ABI 310R Genetic Analyzer (Thermo Fisher Scientific, Inc.).

### Microsatellite instability (MSI) analysis

A multiplex PCR method for the detection of tumors with MSI was performed to determine the MSI status of all CRC tissues using four mononucleotide repeat markers (BAT26, NR21, NR27 and CAT25) as described previously ([@b21-ol-0-0-11365],[@b22-ol-0-0-11365]). Tumors exhibiting MSI in ≥1 mononucleotide repeat marker were classified as MSI phenotype, whereas those without MSI were classified as non-MSI phenotype.

### Analysis of miRNA expression in paired primary tumor and normal colonic tissue samples using miRNA microarray

Total miRNA was isolated from frozen tissue specimens using a miRNeasy Mini kit (Qiagen, Inc.) and analyzed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.) according to the manufacturer\'s protocol. SurePrint G3 Human miRNA 8×60K Rel.16.0 (Agilent Technologies, Inc.) was used to analyze miRNA expression in paired primary tumor and normal colonic tissue samples. The expression level of each probe was calculated as the sum of 20 spots of raw intensity with the background subtracted. Target miRNAs that were not detected in any spots were defined as 'undetected' and allocated an expression level of '0.1'. The data were normalized to the 90th percentile, and target miRNAs that were not detected in all the samples were excluded ([@b9-ol-0-0-11365]).

### Preliminary analysis of the association between miR-31 expression and BRAF mutation using TCGA database

Freely available datasets regarding miRNA expression and somatic mutations of colon adenocarcinoma samples were retrieved from TCGA ([@b23-ol-0-0-11365]). From TCGA database (v1.0), a total of 187 CRC samples had data available regarding *miR-31* expression, among which the *BRAF* mutation profile was available in 170 CRCs on the GDC Data Portal (<https://portal.gdc.cancer.gov/>). Thus, *miR-31* expression in 170 CRC tissues was subsequently analyzed. Of these, 51 CRCs were categorized as having *BRAF* V600E mutation (30%).

### Reverse transcription-quantitative (RT-q)PCR

Total miRNA was isolated from frozen tissue specimens using a miRNeasy Mini kit (Qiagen, Inc.). The expression levels of *miR-31* (Hs_miR-31_1 miScript Primer Assay; Qiagen, Inc.) and *RNU6B* (Hs_RNU6-2_1 miScript Primer Assay; Qiagen, Inc.) were analyzed using miScript primer assays. The cDNA was generated by a miScript II RT Kit (Qiagen, Inc.). RT-qPCR was performed with the gene-specific primers and a miScript SYBR^®^ Green PCR kit (Qiagen, Inc.) using a LightCycler 480 (Roche Diagnostics), according to the manufacturer\'s protocol. Briefly, reactions were incubated in a 96-well plate at 95°C for 15 min, followed by 40 cycles of 95°C for 15 sec, 55°C for 30 sec and 70°C for 30 sec, according to the manufacturer\'s protocol. The quantitative value of miRNA in a given sample was calculated by subtracting that value from the Cq value of *RNU6B*, which served as the internal reference gene. Cq values from duplicate reactions were averaged, and the threshold cycle value (ΔCq) was calculated by subtracting the Cq of the *RNU6B* from the Cq of the target *miR-31*. The ∆∆Cq value of tumor was calculated by subtracting the ∆Cq value of the normal counterpart sample ([@b24-ol-0-0-11365]). The value of 2^−∆∆Cq^ represents the expression relative quotient (RQ) of *miR-31*. Here, the *miR-31* expression level (RQ of *miR-31*) was presented as the ratio of the *miR-31* expression in cancerous tissue vs. adjacent non-cancerous tissue. A *miR-31* expression level \<1 indicated that the expression levels in cancerous tissue were lower compared with that in the paired normal colonic tissue. Conversely, an *miR-31* expression level \>1 indicated higher expression in cancerous tissue compared with that in the paired normal colonic tissue.

### Statistical analysis

Statistical analyses were performed using JMP Pro software (version 14.2; SAS Institute Inc.). The miRNA expression level is presented as the mean RQ, and was measured three times in all samples. Categorical variables were compared using a χ^2^ test. *miR-31* expression levels in *BRAF*-mutant CRC tissues from TCGA were compared with those in *BRAF*-wild type CRC tissues using Dunnett\'s Method. Disease-specific overall survival time (OS) was calculated from the date of initial treatment to the date of death due to primary colon cancer or last follow-up for censored patients (the patients were followed up every month for stage IV cases). Survival data, \<120 months, following initial treatment was used. Survival-based outcomes were analyzed by the Kaplan-Meier method, expressed as medians and compared with log-rank test. Univariate and multivariate analyses were performed using the Cox-proportional hazards model. The hazard ratio (HR) and 95% confidence interval (CI) were calculated from the model, and the significance of the parameters was evaluated using Wald\'s test. All reported P-values were from two-sided tests, and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Identification of miRNAs associated with CRCs expressing the BRAF V600E mutation

Prior to analyzing the miRNA microarray data, six independent CRC specimens were evaluated according to their *KRAS/BRAF* mutational profiles and MSI status, which resulted in six subtypes with different genetic and clinical features ([@b25-ol-0-0-11365]). No MSI tumors were observed to exhibit a *KRAS*-mutation. Therefore, the following specimens were collected: An MSI with *BRAF* V600E mutation, two non-MSI tumors without either *KRAS* or *BRAF* mutation (wild-type), a non-MSI tumor with *BRAF* V600E mutation, and two non-MSI tumor with *KRAS* mutation, each located in the right or left side of the colon. The two normal colonic (right colon and rectum) mucosa specimens were used as controls ([Fig. 2A](#f2-ol-0-0-11365){ref-type="fig"} and [Table SI](#SD1-ol-0-0-11365){ref-type="supplementary-material"}). The miRNA array provided the expression status of a total of 1,368 miRNAs.

To identify miRNAs that were significantly associated with non-MSI tumors containing the *BRAF* V600E mutation, miRNAs exhibiting no expression among the six CRC tissues and the two corresponding normal colorectal mucosae (803 miRNAs), and miRNAs that were expressed in all the tissues (286 miRNAs), were excluded. The cluster analysis revealed that only *miR-31* was significantly upregulated in non-MSI CRC specimens with the *BRAF* V600E mutation (sample ID, 341), while *miR-429, −375, −200a, −200b* and -*192* were downregulated compared with that in the other CRC phenotypes, such as CRCs with wild-type *BRAF*. Generally, molecules that are significantly and specifically upregulated in tumors are useful for screening those tumors via liquid biopsy or other screening tools ([@b26-ol-0-0-11365]). Therefore, subsequent analyses focused on *miR-31* as a candidate prognostic biomarker in the present study.

### Association between miR-31 expression and BRAF-mutant CRC in TCGA database

To confirm whether elevated *miR-31* expression is common in *BRAF*-mutant CRC, miRNA expression and somatic mutations data from colon adenocarcinoma samples retrieved from TCGA were analyzed ([Fig. 2B](#f2-ol-0-0-11365){ref-type="fig"}). From the database, a cohort of 170 patients with CRC were available for analysis of *miR-31* expression with respect to *BRAF* mutation status. Among the 170 CRCs, the value of *miR-31* expression ranged from 0 to 447.6 (median, 6.27). *BRAF* mutation was observed in 51 patients with CRC (30%), and all 51 showed higher *miR-31* expression (median value, 45.47; 95% CI, 20.59--70.35) compared to patients with CRC expressing wild-type *BRAF* (median value, 21.57; 95% CI, 13.09--30.05; P=0.0228).

### Calculation of miR-31 expression in stage IV CRC specimens

To examine at what point during CRC progression do *miR-31* expression levels affect clinical outcomes in advanced CRC, a cohort of 67 patients with stage IV CRCs (out of a total of 598), had both frozen tumor and adjacent normal mucosa tissues available for RNA extraction, were selected ([Fig. 1](#f1-ol-0-0-11365){ref-type="fig"}). Of the 67 stage IV CRC specimens, all of them were non-MSI. The median *miR-31* expression level was 3.45 (mean, 142; range, 0.004--6330.531). Therefore, a cut-off value of 3.5 was used. Cases showing an *miR-31* expression level ≥3.5 were included in the *miR-31* high-expression group, while cases with an *miR-31* expression level \<3.5 were categorized as low expression. According to this classification, 33 and 34 cases were defined as *miR-31* high expression and *miR-31* low expression, respectively. [Table I](#tI-ol-0-0-11365){ref-type="table"} displays the clinicopathological features of patients with stage IV CRCs as classified by *miR-31* expression level. Of the 67 stage IV CRCs, only four had a *BRAF* mutation and were all included in the *miR-31* high expression group; however, the association was not significant. Additionally, there were no significant differences in clinicopathological characteristics between the two groups.

### Clinical outcomes are associated with miR-31 expression status in patients with stage IV CRCs

Among the cohort of 67 patients with stage IV CRCs, the median survival time (MST) was 29 months (95% CI, 19.5--38 months; [Fig. 3A](#f3-ol-0-0-11365){ref-type="fig"}). Stratification of patients according to their *BRAF/KRAS* mutation status was then conducted; the MST of patients with *BRAF*-mutant, *KRAS*-mutant and wild-type CRC was 1.8, 29 and 30 months, respectively ([Fig. 3B](#f3-ol-0-0-11365){ref-type="fig"}; P\<0.0001). Next, clinical outcomes were analyzed with respect to *miR-31* expression status. The MST of the *miR-31* high expression group was 20 months, while that of the *miR-31* low expression group was 38 months ([Fig. 4A](#f4-ol-0-0-11365){ref-type="fig"}; P=0.0314). Of note, the four patients with *BRAF*-mutant CRCs (MST, 1.8 months) were all in the *miR-31* high-expression group, and the prognosis of the *miR-31* high-expression group may have been affected by this subgroup of patients. Therefore, during subsequent prognostic analysis patients with *BRAF*-mutant CRC were excluded. The *miR-31* high expression group still maintained a tendency toward poor prognosis compared with the *miR-31* low-expression group, although it did not reach statistical significance ([Fig. 4B](#f4-ol-0-0-11365){ref-type="fig"}).

Finally, univariate and multivariate analyses were conducted using the Cox-proportional hazards model to determine the factors that influenced poorer outcomes in patients with stage IV CRC ([Table II](#tII-ol-0-0-11365){ref-type="table"}). The univariate analysis revealed that tumors with poor or mucinous histology, multiple distant metastatic sites, the *BRAF* V600E mutation and higher *miR-31* expression levels statistically exhibited a poorer prognosis; however, in the multivariate analysis, only multiple distant metastatic sites and the presence of the *BRAF* V600E mutation, indicated a poorer prognosis.

Discussion
==========

In the present study, the potential of *miR-31* as a prognostic biomarker for patients with advanced CRC was demonstrated, particularly in patients with stage IV of the disease. *miR-31* is located on chromosome 9p21.3 and is reportedly deregulated in various types of human cancer, for example, esophageal, breast, ovarian and gastric cancers ([@b3-ol-0-0-11365],[@b27-ol-0-0-11365]--[@b30-ol-0-0-11365]). Moreover, in CRC, an association has been reported between upregulation of *miR-31* and poor tumor differentiation ([@b13-ol-0-0-11365]), oncogenic potential ([@b13-ol-0-0-11365],[@b31-ol-0-0-11365]--[@b34-ol-0-0-11365]), deeper invasion ([@b34-ol-0-0-11365],[@b35-ol-0-0-11365]) and advanced disease stages ([@b31-ol-0-0-11365],[@b34-ol-0-0-11365],[@b35-ol-0-0-11365]).

In the advanced stages of CRC, the presence of *BRAF* mutations is demonstrated to be a poor prognostic factor ([@b14-ol-0-0-11365]--[@b18-ol-0-0-11365]), so specific miRNAs that are significantly associated with *BRAF* mutations were investigated in the present study. The results obtained from a miRNA array analysis revealed that *miR-31* was upregulated in *BRAF*-mutant CRC tissues compared with that in other CRC subtypes, such as *KRAS*-mutant or wild-type CRCs. The association between *miR-31* and *BRAF* mutations was also confirmed in a dataset comprising information on 170 patients with CRC, retrieved from TCGA database.

In addition to its association with the *BRAF* oncogene, *miR-31* has been demonstrated to bind to the 3′-untranslated region of special AT-rich sequence-binding protein 2 (SATB2), which is a nuclear matrix-associated transcription factor and epigenetic regulator, downregulating its expression at both the mRNA and protein level ([@b36-ol-0-0-11365]). SATB2 was originally identified as a highly tissue-specific protein, predominantly expressed in glandular cells of the lower gastrointestinal tract, and high expression of SATB2 is an accurate prognostic marker in CRC ([@b37-ol-0-0-11365],[@b38-ol-0-0-11365]).

Another target of *miR-31* is RAS p21 GTPase-activating protein 1 (RASA1), which is a negative regulator of the RAS-RAF-MEK-ERK signal pathway ([@b39-ol-0-0-11365]). Overexpression of *miR-31* downregulates RASA1 protein but not *RASA1* mRNA, suggesting that *miR-31* regulates RASA1 expression via a post-transcriptional mechanism. RASA1, with its C-terminal GAP domain, has the ability to stimulate the GTPase activity of normal RAS p21, which results in the inactivation of RAS. Thus, overexpression of *miR-31* in CRC may repress RASA1 and consequently upregulate the RAS pathway to promote tumor cell proliferation. Furthermore, *miR-31* promotes epithelial-mesenchymal transition (EMT) ([@b34-ol-0-0-11365],[@b40-ol-0-0-11365]). Cottonham *et al* ([@b34-ol-0-0-11365]) reported that CRC cell lines with elevated *miR-31* expression undergo EMT (a factor associated with distant metastasis) in response to transforming growth factor (TGF)-β, without influencing the TGF-β pathway. Meng *et al* ([@b41-ol-0-0-11365]) reported that *miR-31* was upregulated in lung adenocarcinoma tissues from patients with lymph node metastases, compared with those without. Additionally, *in vitro* functional assays demonstrated that *miR-31* increased cell migration, invasiveness and proliferation in an ERK1/2 signaling-dependent manner ([@b40-ol-0-0-11365]).

Thus, upregulation of *miR-31* may enhance tumor development, as well as the malignant potential of a tumor, via inhibition of SATAB2 and RASA1, enhancement of EMT and upregulation of BRAF expression. Particularly, *miR-31* upregulation is commonly observed in *BRAF*-mutant CRCs, which may enhance the downstream proteins of RAS-RAF signal cascade.

Regarding molecular targeting therapies, there are several reports indicating the influence of the expression status of *miR-31* (either −3p alone or both −3p and −5p) on the sensitivity of metastatic CRC (with wild-type *RAS)* to anti-EGFR therapy ([@b42-ol-0-0-11365]--[@b44-ol-0-0-11365]). Patients with higher *miR-31* expression levels exhibited poorer outcomes during treatment with anti-EGFR therapy. As *miR-31* upregulates BRAF protein levels irrespective of the *RAS/BRAF* mutation status and inhibits *RASA1* mRNA (which inactivates activated RAS by stimulating GTPase) ([@b13-ol-0-0-11365],[@b39-ol-0-0-11365]), it is hypothesized that upregulation of *miR-31* inhibits the efficacy of anti-EGFR therapy, and acts in a manner similar to oncogenic mutations in the *RAS* and *RAF* genes.

To the best of our knowledge, the most effective treatment strategy for patients with stage IV CRC and BRAF mutations, which may be associated with high *miR-31* expression levels ([@b13-ol-0-0-11365]), is currently unknown. The answer may exist in a recent clinical trial for unresectable patients with *BRAF* V600E mutant CRC, called the BEACON study ([@b45-ol-0-0-11365]). *BRAF* inhibition has been revealed to improve clinical outcomes in patients with melanoma and non-small cell lung cancer that have a *BRAF* V600 mutation; however, in patients with CRC, BRAF inhibition has only conferred a marginal improvement in the reduction of tumor burden ([@b46-ol-0-0-11365]--[@b53-ol-0-0-11365]). Notably, *in vitro* studies demonstrated that in *BRAF* V600E-mutant CRC cells, BRAF inhibition results in the rapid feedback activation of EGFR, permitting sustained MAPK activation and continued cell proliferation; however, combined inhibition of BRAF and EGFR resulted in synergistic inhibition of tumor growth in *BRAF* V600E mutant CRC xenograft models ([@b54-ol-0-0-11365],[@b55-ol-0-0-11365]). Subsequent clinical studies of EGFR-targeted therapies, combined with the BRAF inhibitors vemurafenib or dabrafenib, confirmed that addition of an EGFR-targeted therapy may improve the activity of BRAF inhibition in *BRAF* V600E-mutant CRC ([@b55-ol-0-0-11365]--[@b57-ol-0-0-11365]). In the BEACON study ([@b45-ol-0-0-11365]), patients with CRC and the *BRAF* V600E mutation, who had experienced treatment failure with one or two prior chemotherapy regimens, were recruited and treated with three molecular target agents, encorafenib (a BRAF inhibitor), binimetinib (a MEK inhibitor) and cetuximab (an EGFR inhibitor). In 29 patients with *BRAF* V600E mutant tumors, the overall response rate was 48%, the median progression-free survival was 8.0 months and the median OS time was 15.3 months ([@b45-ol-0-0-11365]). This indicates that the *BRAF* V600E mutation serves as a facilitator of CRC progression and therapies are required that inhibit the feedback activation of RAS-RAF signal cascade.

The present study demonstrated that high *miR-31* expression was associated with *BRAF* V600E mutation in patients with stage IV CRC, but also indicated a poor prognosis, irrespective of *BRAF* mutation status. Additionally, an inhibitor to *miR-31* may confer a clinical benefit on patients with CRC with *BRAF* V600E mutation or high miR-31 expression levels, perhaps as part of a combination therapy alongside BRAF inhibitors, MEK inhibitors and EGFR inhibitors.

In the present study, despite the small population size, analysis of miRNA microarray data and relevant samples from TCGA database showed the reproducible result that high *miR-31* expression was associated with a *BRAF* mutation and poor outcome in CRC, as demonstrated by a previous study ([@b13-ol-0-0-11365]). The results from the current strongly indicate that the expression level of *miR-31* in the primary cancer site is a promising prognostic factor for CRC regardless of the RAS/*BRAF* mutation profile as well as a predictive factor for anti-EGFR treatment in CRCs with wild-type *RAS/BRAF*. Thus, *miR-31* may represent a favorable biomarker and a promising therapeutic target in patients with CRC.
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###### 

Clinicopathological features of 67 patients with stage IV CRC stratified by *miR-31* expression level.

                                                    *miR-31* expression level, n (%)                   
  --------------------------------- --------------- ---------------------------------- --------------- ----------------
  Age, years                                                                                           
    Mean (range)                    64.1 (35--85)   62.9 (41--85)                      65.3 (35--82)   
    \<65                            28 (41.8)       17 (50.0)                          11 (33.3)       0.218
    ≥65                             39 (58.2)       17 (50.0)                          22 (66.7)       
  Gender                                                                                               0.621
    Female                          26 (38.8)       12 (35.3)                          14 (42.4)       
    Male                            41 (61.2)       22 (64.7)                          19 (57.6)       
  Serum CEA level, ng/µl                                                                               0.262
    \<5.0                           17 (25.4)       11 (32.4)                          6 (18.2)        
    ≥5.0                            50 (74.6)       23 (67.6)                          27 (81.8)       
  Tumor location                                                                                       0.392
    Right                           15 (22.4)       6 (17.6)                           9 (27.3)        
    Left                            52 (77.6)       28 (82.4)                          24 (72.7)       
  Histology                                                                                            0.186
    Well or moderate                57 (85.1)       31 (91.2)                          26 (78.8)       
    Poor or mucinous                10 (14.9)       3 (8.8)                            7 (21.2)        
  No. of distant metastatic sites                                                                      0.194
    Single                          46 (68.7)       26 (76.5)                          20 (60.6)       
    Multiple                        21 (31.3)       8 (23.5)                           13 (39.4)       
  T factor                                                                                             0.2
    1                               1 (1.5)         0 (0.0)                            1 (3.0)         
    2                               4 (6.0)         3 (8.8)                            1 (3.0)         
    3                               38 (56.7)       22 (64.7)                          16 (48.5)       
    4a                              15 (22.4)       7 (20.6)                           8 (24.2)        
    4b                              9 (13.4)        2 (5.9)                            7 (21.2)        
  N factor                                                                                             0.437
    0                               13 (19.4)       9 (26.5)                           4 (13.3)        
    1a                              11 (16.4)       5 (14.7)                           6 (18.2)        
    1b                              14 (20.9)       6 (17.6)                           8 (24.2)        
    1c                              1 (1.5)         1 (2.9)                            0 (0.0)         
    2a                              13 (19.4)       4 (11.8)                           9 (27.3)        
    2b                              12 (17.9)       7 (20.6)                           5 (15.2)        
    X                               3 (4.5)         2 (5.9)                            1 (3.0)         
  M factor                                                                                             0.447
    1a                              44 (65.7)       24 (54.5)                          20 (45.5)       
    1b                              23 (34.3)       10 (43.5)                          13 (56.5)       
  MSI status                                                                                           Not calculated
    MSI                             0 (0.0)         0 (0.0)                            0 (0.0)         
    Non-MSI                         67 (100.0)      34 (100)                           33 (100)        
  *KRAS/RAF* mutation status                                                                           0.0608
    *KRAS* mutation                 15 (22.4)       10 (29.4)                          5 (15.2)        
    *BRAF* mutation                 4 (6.0)         0 (0)                              4 (12.1)        
    Wild-type                       48 (71.6)       24 (70.6)                          24 (72.7)       

P-values were calculated using χ^2^ test. miR, microRNA; *KRAS*, KRAS proto-oncogene, GTPase; *BRAF*, B-Raf proto-oncogene, serine/threonine kinase; MSI, microsatellite instability. T, N and M factor denotes the depth of invasion, the regional lymph node metastasis and the presence or otherwise of distant metastasis defied by the AJCC cancer staging ([@b19-ol-0-0-11365]). X denotes unclassified of N factor.

###### 

Cox regression analyses of 67 patients with stage IV colorectal cancer.

                                            Univariate            Multivariate                                                                  
  ----------------------------------------- --------------------- ------------------------------------------------------ ---------------------- ------------------------------------------------------
  Age, years                                                                                                                                    
    \>65 vs. \<65                           1.78 (0.86--3.69)     0.1197                                                 1.41 (0.61--3.26)      0.4244
  Sex                                                                                                                                           
    Female vs. male                         1.19 (0.59--2.43)     0.6249                                                 1.18 (0.52--2.69)      0.6891
  Serum CEA level, ng/µl                                                                                                                        
    \>5 vs. \<5                             1.24 (0.55--2.78)     0.5999                                                 1.23 (0.53--2.87)      0.6243
  Tumor location                                                                                                                                
    Right vs. left                          1.10 (0.47--2.55)     0.8252                                                 0.34 (0.08--1.42)      0.1394
  Histology                                                                                                                                     
    Poor or mucinous vs. well or moderate   3.16 (1.33--7.52)     0.0094^[a](#tfn2-ol-0-0-11365){ref-type="table-fn"}^   1.83 (0.59--5.67)      0.2941
  No. of distant metastatic sites                                                                                                               
    Multiple vs. single                     2.95 (1.46--5.96)     0.0027^[a](#tfn2-ol-0-0-11365){ref-type="table-fn"}^   2.84 (1.31--6.17)      0.0083^[a](#tfn2-ol-0-0-11365){ref-type="table-fn"}^
  *KRAS/BRAF* mutation status                                                                                                                   
    *BRAF* mutation vs. *KRAS* mutation     12.73 (2.68--60.37)   0.0014^[a](#tfn2-ol-0-0-11365){ref-type="table-fn"}^   13.18 (2.11--82.39)    0.0058^[a](#tfn2-ol-0-0-11365){ref-type="table-fn"}^
    *KRAS* mutation vs. wild-type           1.11 (0.47--2.58)     0.8152                                                 2.20 (0.73--6.64)      0.1611
    *BRAF* mutation vs. wild-type           14.08 (3.37--58.85)   0.0003^[b](#tfn3-ol-0-0-11365){ref-type="table-fn"}^   29.03 (3.58--235.29)   0.0016^[a](#tfn2-ol-0-0-11365){ref-type="table-fn"}^
  *miR-31* expression level                                                                                                                     
    High vs. low                            2.12 (1.05--4.29)     0.0356^[a](#tfn2-ol-0-0-11365){ref-type="table-fn"}^   1.48 (0.67--3.29)      0.3358

P\<0.05.

P\<0.001. miR, microRNA; HR, hazard ratio; CI, confidence interval; miR, microRNA; *KRAS*, KRAS proto-oncogene, GTPase; *BRAF*, B-Raf proto-oncogene, serine/threonine kinase; MSI, microsatellite instability.
